These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 28245033)

  • 1. Erratum to Rutten et al. "Platelet density per monocyte predicts adverse events in patients after percutaneous coronary intervention" (Thromb Haemost 2016; 115: 353-360).
    Thromb Haemost; 2017 Feb; 117(3):641. PubMed ID: 28245033
    [No Abstract]   [Full Text] [Related]  

  • 2. Platelet density per monocyte predicts adverse events in patients after percutaneous coronary intervention.
    Rutten B; Roest M; McClellan EA; Sels JW; Stubbs A; Jukema JW; Doevendans PA; Waltenberger J; van Zonneveld AJ; Pasterkamp G; De Groot PG; Hoefer IE
    Thromb Haemost; 2016 Jan; 115(2):353-60. PubMed ID: 26423019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracorporeal assays of thrombosis.
    Badimon L; Padro T; Vilahur G
    Methods Mol Biol; 2012; 788():43-57. PubMed ID: 22130699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erratum to Kooistra et al. "Long-term quality of VKA treatment and clinical outcome after extreme overanticoagulation in 14,777 AF and VTE patients" (Thromb Haemost 2015; 113: 881-890).
    Thromb Haemost; 2015 Aug; 114(3):656. PubMed ID: 26320573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erratum to Palareti et al. "The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. A real-life inception cohort study" (Thromb Haemost 2016; 115: 1101-1108).
    Thromb Haemost; 2016 Aug; 116(2):396. PubMed ID: 27476951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erratum to Fischer et al. "Inhibitor development in nonsevere haemophilia across Europe" (Thromb Haemost 2015; 114: 670-675).
    Thromb Haemost; 2016 Mar; 115(3):684. PubMed ID: 26922949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erratum to Loboda et al. "Carbon monoxide: pro- or anti-angiogenic agent? Comment on Ahmad et al. (Thromb Haemost 2015; 113: 329-337).
    Thromb Haemost; 2016; 116(1):203. PubMed ID: 27374429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erratum to Heit et al. "Reasons for the persistent incidence of venous thromboembolism" (Thromb Haemost 2017; 117: 390-400).
    Thromb Haemost; 2017 Feb; 117(3):643. PubMed ID: 28245032
    [No Abstract]   [Full Text] [Related]  

  • 9. Erratum to Sala et al. "MiR-143/145 deficiency attenuates the progression of atherosclerosis in Ldlr-/-mice" (Thromb Haemost 2014; 112: 796-802).
    Thromb Haemost; 2015 Jul; 114(1):210. PubMed ID: 26125660
    [No Abstract]   [Full Text] [Related]  

  • 10. Erratum to Giangrande et al. "Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A" (Thromb Haemost 2017; 117: 252-261).
    Thromb Haemost; 2017 Jun; 117(6):1163. PubMed ID: 31117130
    [No Abstract]   [Full Text] [Related]  

  • 11. Erratum to Hillis et al. "Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants" (Thromb Haemost 2014; 113: 1193-1201).
    Thromb Haemost; 2015 Jul; 114(1):210. PubMed ID: 26125661
    [No Abstract]   [Full Text] [Related]  

  • 12. Erratum to Pottegård et al. "Antithrombotic drugs and subarachnoid haemorrhage risk: A nationwide case-control study in Denmark" (Thromb Haemost 2014; 5: 1064-1075).
    Thromb Haemost; 2016 May; 115(5):1079. PubMed ID: 27137945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erratum to Parasrampuria et al. "Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis" (Thromb Haemost 2015; 113: 719-727).
    Thromb Haemost; 2017 Apr; 117(4):821. PubMed ID: 28367580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erratum to Barco et al. "Home treatment of patients with lowrisk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot-PE Trial" (Thromb Haemost 2016; 116: 191-197).
    Thromb Haemost; 2016 Sep; 116(4):775. PubMed ID: 27670439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erratum to "Adipokines at the crossroad between obesity and cardiovascular disease" (Thromb Haemost 2015; 113: 553-566).
    Molica F; Morel S; Kwak BR; Rohner-Jeanrenaud F; Steffens S
    Thromb Haemost; 2015 Apr; 113(4):909. PubMed ID: 25822650
    [No Abstract]   [Full Text] [Related]  

  • 16. Corrigendum to GoldVariants, a resource for sharing rare genetic variants detected in bleeding, thrombotic, and platelet disorders: Communication from the ISTH SSC Subcommittee on Genomics in Thrombosis and Hemostasis [J Thromb Haemost. 2021 Oct;19(10):2612-2617].
    Megy K; Downes K; Morel-Kopp MC; Bastida JM; Brooks S; Bury L; Leinoe E; Gomez K; Morgan NV; Othman M; Ouwehand WH; Botero JP; Rivera J; Schulze H; Trégouët DA; Freson K
    J Thromb Haemost; 2023 Apr; 21(4):1067. PubMed ID: 36737374
    [No Abstract]   [Full Text] [Related]  

  • 17. Platelet-monocyte aggregates predict troponin rise after percutaneous coronary intervention and are inhibited by Abciximab.
    Ray MJ; Walters DL; Bett JN; Cameron J; Wood P; Aroney CN
    Int J Cardiol; 2005 May; 101(2):249-55. PubMed ID: 15882672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total Thrombus-formation Analysis System Predicts Periprocedural Bleeding Events in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
    Oimatsu Y; Kaikita K; Ishii M; Mitsuse T; Ito M; Arima Y; Sueta D; Takahashi A; Iwashita S; Yamamoto E; Kojima S; Hokimoto S; Tsujita K
    J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28438734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired thrombolytic status predicts adverse cardiac events in patients undergoing primary percutaneous coronary intervention.
    Christopoulos C; Farag M; Sullivan K; Wellsted D; Gorog DA
    Thromb Haemost; 2017 Feb; 117(3):457-470. PubMed ID: 28004059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study.
    Patti G; Nusca A; Mangiacapra F; Gatto L; D'Ambrosio A; Di Sciascio G
    J Am Coll Cardiol; 2008 Sep; 52(14):1128-33. PubMed ID: 18804738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.